Skip Navigation LinksHome > December 2012 - Volume 112 - Issue 12 > Risk of Seizure with the MS Drug Dalfampridine
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000423498.23146.3d
Drug Watch

Risk of Seizure with the MS Drug Dalfampridine

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* The Food and Drug Administration has strengthened its warnings related to the risk of seizures from the multiple sclerosis drug dalfampridine (Ampyra). The drug's label now warns that even mild renal impairment can allow serum levels of the drug to increase enough to induce seizures. To minimize the risk of seizures the patient's creatinine clearance should be determined prior to the start of dalfampridine therapy and at least yearly while she or he is receiving the drug.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics